logo

Fibrogen Inc. (FGEN)



Trade FGEN now with
  Date
  Headline
4/20/2022 7:47:32 AM FibroGen Announces Completion Of Patient Enrollment In ZEPHYRUS-1 Study Of Pamrevlumab
8/25/2021 7:13:05 AM FibroGen Reports Positive Results From Phase 2 Trial Of Roxadustat For Chemotherapy Induced Anemia
8/11/2021 7:26:42 AM FibroGen Gets Complete Response Letter From FDA For Roxadustat For Anemia Of Chronic Kidney Disease
7/12/2021 7:06:03 AM FibroGen Appoints John Hunter As Chief Scientific Officer
6/25/2021 9:00:25 AM Astellas Pharma, FibroGen: CHMP Of EMA Adopted Positive Opinion Relating To Use Of Roxadustat
4/12/2021 7:23:35 AM FibroGen Says FDA Granted Fast Track Designation For Anti-CTGF Antibody, Pamrevlumab
6/26/2017 7:22:30 AM William Blair Reiterates FibroGen Inc. (FGEN) At Outperform
8/9/2016 10:44:35 AM RBC Capital Markets Is Lowering FibroGen Inc. (FGEN) Q4 16 Rev. Estimate To 25.0 M From 43.0 M
8/9/2016 10:44:21 AM RBC Capital Markets Is Cutting FibroGen Inc. (FGEN) Q3 16 Rev. Estimate To 23.0 M From 32.0 M
8/9/2016 10:44:07 AM RBC Capital Markets Is Lowering FibroGen Inc. (FGEN) 2017 Rev. Estimate To 162.0 M From 205.0 M
8/9/2016 10:43:28 AM RBC Capital Markets Is Cutting FibroGen Inc. (FGEN) 2016 Rev. Estimate To 165.6 M From 176.3 M
8/9/2016 10:43:13 AM RBC Capital Markets Is Cutting FibroGen Inc. (FGEN) Q4 16 Estimate To -0.73 From -0.19
8/9/2016 10:42:59 AM RBC Capital Markets Is Lowering FibroGen Inc. (FGEN) Q3 16 Estimate To -0.72 From -0.32
8/9/2016 10:42:48 AM RBC Capital Markets Is Lowering FibroGen Inc. (FGEN) 2017 Estimate To -2.30 From -0.62